Simulations Plus Osake

Simulations Plus Termiini P/E

Forward P/E -suhde yhtiöstä Simulations Plus (SLP) 16.8.2026 päivämäärällä on −3,83. Edellisenä vuonna Forward P/E -suhde oli 24,87 — muutos −115,38 % (matalampi).

Termiini P/E

−3,83

YoY

−115,38%

Viimeksi päivitetty:

Forward P/E -suhde yhtiöstä Simulations Plus on 2026 −3,83 . Forward P/E -suhde yhtiöstä Simulations Plus oli 2025 24,87 . Se laskee −115,38% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Simulations Plus Osakeanalyysi

Mitä Simulations Plus tekee? Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health." Simulations Plus on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Simulations Plus osakkeesta

Yhtiön Simulations Plus Forward P/E -suhde on −3,83 vuonna 2026.

Forward P/E -suhde yhtiöstä Simulations Plus muuttui arvosta 24,87 arvoon −3,83, mikä edustaa −115,38 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää Forward P/E -suhde Simulations Plus:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

Forward P/E käyttää arvioituja tulevia voittoja osakkeen arvostukseen. Pienempi forward P/E peräkkäiseen P/E:hen verrattuna viittaa analyytikkojen odottavan tuloksen kasvua.

Arvioidakseen Forward P/E -suhde:n, on olennaista verrata sitä saman alan ja sektorin kilpailijoihin. Eulerpoolissa voit löytää suoria alan vertailuja Forward P/E -suhde:lle.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata Forward P/E -suhde:n Simulations Plus alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Access this data via the Eulerpool API

Arvostus — Simulations Plus

Kaikki tunnusluvut — Simulations Plus